Tonix Pharmaceuticals Holding Corp (TNXP) shares surged on Tuesday after securing a $34 million research collaboration contract with X-Chem from the U.S. Department of Defense. The collaboration will accelerate the development of Tonix’s broad-spectrum antiviral program, TNX-4200, utilizing AI and machine learning technology.
The global hepatitis therapeutics market is projected to reach US$ 21.9 Bn by 2031, driven by increasing incidence of hepatitis B and C, advancements in treatment modalities, and rising awareness. North America is leading the market due to a high prevalence of the disease and robust healthcare infrastructure.
